SCHEMBL21836075

SCHEMBL21836075

O=C(N[C@H]1CCCC[C@H]1O)c1cccn2c(=O)c3cc(-c4ccncc4)ccc3nc12

nearest known ligand 0.48

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
POLR1A O95602 17/20 0.48
CHRM1 P11229 1/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21836087 0.89 POLR1A (0.58) POLR1AKMT2AMEN1ALDH1A1
SCHEMBL21836056 0.88 POLR1A (0.57) POLR1AKMT2AMEN1ALDH1A1
SCHEMBL21836089 0.85 ALDH1A1 (0.61) POLR1AKMT2AMEN1ALDH1A1NPSR1
SCHEMBL21836102 0.85 POLR1A (0.50) POLR1AKMT2AMEN1ALDH1A1NPSR1
SCHEMBL21836079 0.85 POLR1A (0.50) POLR1AKMT2AMEN1ALDH1A1NPSR1
SCHEMBL21836083 0.85 POLR1A (0.50) POLR1AKMT2AMEN1ALDH1A1NPSR1
SCHEMBL21836078 0.85 POLR1A (0.50) POLR1AKMT2AMEN1ALDH1A1NPSR1
SCHEMBL21836070 0.85 POLR1A (0.50) POLR1AKMT2AMEN1ALDH1A1NPSR1
SCHEMBL21798906 0.83 POLR1A (0.55) POLR1AKMT2AMEN1ALDH1A1NPSR1
SCHEMBL21798914 0.83 POLR1A (0.55) POLR1AKMT2AMEN1ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111247143-B Pyridoquinazoline derivatives useful as inhibitors of protein kinases 昂科斯特拉公司 2022-07-05 CN claimed
US-11021479-B2 Pyridoquinazoline derivatives useful as protein kinase inhibitors ONCOSTELLAE, S.L. (ES) 2021-06-01 US claimed
EP-3632912-B1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS ONCOSTELLAE S L (ES) 2021-03-17 EP claimed
CN-111247143-A Pyridoquinazoline derivatives useful as inhibitors of protein kinases 昂科斯特拉公司 2020-06-05 CN claimed
US-20200148676-A1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS ONCOSTELLAE, S.L. (ES) 2020-05-14 US claimed
EP-3632912-A1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS Oncostellae, S.L. (ES) 2020-04-08 EP claimed
CN-111247143-B Pyridoquinazoline derivatives useful as inhibitors of protein kinases 昂科斯特拉公司 2022-07-05 CN disclosed
US-11021479-B2 Pyridoquinazoline derivatives useful as protein kinase inhibitors ONCOSTELLAE, S.L. (ES) 2021-06-01 US disclosed
EP-3632912-B1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS ONCOSTELLAE S L (ES) 2021-03-17 EP disclosed
CN-111247143-A Pyridoquinazoline derivatives useful as inhibitors of protein kinases 昂科斯特拉公司 2020-06-05 CN disclosed
US-20200148676-A1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS ONCOSTELLAE, S.L. (ES) 2020-05-14 US disclosed
EP-3632912-A1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS Oncostellae, S.L. (ES) 2020-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148676-A1 PYRIDOQUINAZOLINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS MAP4K2, MAP4K1, MAP4K3 POLR1A 1623/4885CHRM1 3270/4885KMT2A 1202/4885
US-11021479-B2 Pyridoquinazoline derivatives useful as protein kinase inhibitors MAP4K2, MAP4K1, MAP4K3 POLR1A 1623/4885CHRM1 3270/4885KMT2A 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.